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MaOBJECTIVES This study sought to compare the effect of paclitaxel-coated balloon (PCB) concentration on tissue levels
and vascular healing using 3 different PCB technologies (In.Pact Paciﬁc ¼ 3 mg/mm2, Lutonix ¼ 2 mg/mm2 and Ranger ¼
2 mg/mm2) in the experimental setting.
BACKGROUND The optimal therapeutic dose for PCB use has not been determined yet.
METHODS Paclitaxel tissue levels were measured up to 60 days following PCB inﬂation (Ranger and In.Pact Paciﬁc) in
the superﬁcial femoral artery of healthy swine (18 swine, 36 vessels). The familial hypercholesterolemic swine model of
superﬁcial femoral artery in-stent restenosis (6 swine, 24 vessels) was used in the efﬁcacy study. Two weeks following
bare-metal stent implantation, each in-stent restenosis site was randomly treated with a PCB or an uncoated control
balloon (Sterling). Quantitative vascular analysis and histology evaluation was performed 28 days following PCB
treatment.
RESULTS All PCB technologies displayed comparable paclitaxel tissue levels 4 h following balloon inﬂation. At 28 days,
all PCB had achieved therapeutic tissue levels; however, the In.Pact PCB resulted in higher tissue concentrations than did
the other PCB groups at all time points. Neointimal inhibition by histology was decreased in all PCB groups compared
with the control group, with a greater decrease in the In.Pact group. However, the neointima was more mature and
contained less peri-strut ﬁbrin deposits in both 2-mg/mm2 PCB groups.
CONCLUSIONS Compared with the clinically established PCB dose, lower-dose PCB technologies achieve lower long-
term tissue levels but comparable degrees of neointimal inhibition and fewer ﬁbrin deposits. The impact of these ﬁndings
in restenosis reduction and clinical outcomes needs to be further investigated. (J Am Coll Cardiol Intv 2015;8:1115–23)
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ABBR EV I A T I ON S
AND ACRONYMS
ANOVA = analysis of variance
PCB = paclitaxel coated
balloon
QVA = quantitative vascular
analysis
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1116E arly clinical trials demonstrated theclinical efﬁcacy of a paclitaxel-coated balloon (PCB) in the femoro-
popliteal arterial territory (1–3). The original
coating formulation used in these studies
(iopromide as a carrier at a dose of 3 mg/mm2)
was highly crystalline, achieved high tissue
levels over time, and produced a high numberof coating particles following balloon inﬂation (4–7).
Newer generation PCB technologies have reduced
both paclitaxel concentration and coating crystallinity
aiming to decrease vascular toxicity and the produc-
tion of coating microparticles. However, although the
pharmacokinetic proﬁles and clinical efﬁcacies of
these ﬁrst-generation technologies are well docu-
mented (1,8,9), the biological effects of these techno-
logical changes on clinical performance are still
unknown. Recent studies suggest that not only efﬁ-
cient tissue transfer, but also sustained drug retention
play a critical role in the clinical efﬁcacy of PCB tech-
nologies (5,7,10). Therefore, understanding the impact
of reducing paclitaxel dose on vascular healing is crit-
ical for the successful development of future local
drug delivery technologies. In this study, we aimed
to study the biological effect of paclitaxel concen-
tration and coating type on drug tissue levels and
neointimal inhibition using several experimental
methodologies.
METHODS
PACLITAXEL-COATED BALLOON DESCRIPTION. The
following PCB technologies were used in this study: 1)
Ranger (2 mg/mm2; Boston Scientiﬁc, Marlborough,
Massachusetts); 2) In.Pact (3 mg/mm2; Medtronic,
Dublin, Ireland); and 3) Lutonix (2 mg/mm2; BARD,
Tempe, Arizona). Each treatment device uses
different coating techniques and excipients. The
Ranger PCB employs an acetyl tributyl citrate as the
excipient. The In.Pact PCB uses urea as the excipient.
The Lutonix PCB uses a non-polymer-based poly-
sorbate/sorbitol as the excipient. The control device
used was an uncoated balloon (Sterling, Boston Sci-
entiﬁc). All balloons used in all the studies were 5 to
6  40 mm. The self-expanding stents used in the
efﬁcacy study were 5 to 6  20 mm (EverFlex, eve3
Endovascular, Plymouth, Minnesota).
IN VITRO COATING PARTICULATE FORMATION
STUDY. Coating characterization (n ¼ 3 per group) was
performed using an in vitro coating particulate testing
bench top model. Phosphate-buffered saline (pH 7.4)
at 37C was circulated at 150 ml/min through a glass
iliofemoral model using a contralateral approach. Anin-line 47-mm diameter black polycarbonate ﬁlter
(5.0-mm pore size) was used to collect downstream
particulate. Each PCB (6.0  40 mm) was inserted into
individual 5.5-mm inner diameter Tecothane tubes
(Lubrizol Advanced Materials, Inc., Cleveland Ohio)
through a new introducer sheath, tracked (2 min), and
inﬂated per their nominal label for 45 s. After deﬂa-
tion, the devices were withdrawn from the model and
the sheath was ﬂushed with 20 ml of media. Filters
were collected, dried, and then imaged (25) using a
Clemex Vision Particle Analyzer (Longueuil, Quebec,
Canada) with Leica DM4000M microscope (Leica
Microsystems, Buffalo Grove, Illinois). All particles
were highlighted with green color for better visuali-
zation. The particulate images were further ana-
lyzed for the size and number (Vision PE, version
5.0 software, Clemex); the size of a particle was esti-
mated by converting the number of neighboring pixels
with similar color associated with a particle to an
equivalent diameter. The average number of particu-
lates above 300 mm in size was plotted to illustrate the
different levels of systemic particles for the devices.
PHARMACOKINETIC STUDY IN FEMORAL ARTERIES.
Arterial paclitaxel concentrations were determined
following PCB delivery (Ranger or In.Pact) in the
femoral territory of swine. The results were compared
with well-established historical data published for the
Lutonix PCB technology (11). Arterial tissue concen-
trations of paclitaxel were measured at 4 h and 1, 7,
21, 45, and 60 days. A total of 3 animals per time point
(18 animals) were included and received PCB delivery
in every femoral artery (36 vessels). At sacriﬁce, in-
dividual arteries were harvested, homogenized,
extracted, and quantiﬁed by mass spectrometer for
arterial paclitaxel concentration.
HYPERCHOLESTEROLEMIC SWINE MODEL. A total of 6
familial hypercholesterolemic swine obtained from
the University of Wisconsin, Department of Animal
Sciences were used in this study. The genotypic and
clinical features of this model have been already
published (12,13). For this study, animals were
maintained on a low-grade cholesterol pig chow in
order to increase the cholesterol levels and to accel-
erate the disease process. In this study, younger an-
imals were used (w8 months) as based on previous
studies demonstrated the accelerated progression of
neointimal proliferation following vascular injury
despite the absence of signiﬁcant atherosclerotic
burden at this age (14,15).
IN-STENT RESTENOSIS MODEL AND TREATMENT.
Figure 1 describes the study design. The study was
approved by the Institutional Animal Care and Use
FIGURE 1 In Vivo Efﬁcacy Study Design
Two weeks following bare-metal stent (BMS) implantation, all in-stent restenosis segments were treated with drug-coated balloon or plain old
balloon angioplasty (POBA). Tissue was harvested at 4 weeks following treatment. FH ¼ familial hypercholesterolemic; SFA ¼ superﬁcial
femoral artery.
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1117Committee of the Skirball Center for Innovation. All
animals received standard care in accordance with the
Institute of Laboratory Animal Resources guidelines
(16). The diet, animal preparation, and procedural
methodologies followed in this protocol have been
previously published (7,17). Following vessel sizing
by quantitative vascular analysis (QVA), oversized
balloon injury (1.25:1.0 balloon-to-artery ratio) was
applied to the target area. Each balloon inﬂation was
followed by the deployment of a self-expanding bare-
metal stents in each injured segment. After 14 days, all
in-stent restenosis segmentswere treatedwith either a
PCB or uncoated control balloon for a total of 60  3 s
(target of 1.2:1.0 balloon-to-artery ratio). Four weeks
later (day 42), terminal angiography of all treated sites
was performed, followed by termination and histo-
logical analysis of treatment sites.
ANGIOGRAPHIC ANALYSIS. QVA was performed at 3
different time points for the angiographic analysis by
experienced angiographic technicians previously
qualiﬁed by the Cardiovascular Research Foundation
core lab. On-line QVA at day 0 was performed at the
Advantage Workstation (AW 4.3-07, GE Healthcare,Waukesha, Wisconsin). QVA analysis at other time
points was done using CAAS software (Medis Medical
Imaging Systems Inc., Leiden, the Netherlands). All
QVA analysis methodology used in this study has
been already published (5,7). Percentage diameter
stenosis at pre-procedure (day 14) and termination
(day 42) was calculated as: (1 – [minimal lumen
diameter /reference vessel diameter]  100%) and the
late lumen loss was calculated as a difference be-
tween minimal lumen diameter at day 42 and day 14.
HISTOLOGICAL ANALYSIS. The histological analysis
of this study was conducted in a blind fashion by an
independent pathology laboratory (Alizee Pathology,
LLC, Thurmont, Maryland). Following euthanasia,
arterial samples were harvested and processed
following previously standardized methodologies (11).
All slides were stained with hematoxylin and eosin
and elastic trichrome. For histomorphometry, the
cross-sectional areas (external elastic lamina,
internal elastic lamina, stent area, and lumen area)
of each section were measured. Neointimal thick-
ness was calculated as: [(internal elastic lamina diam-
eter – lumen diameter)/2] 1,000. Neointimal area was
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Qualitative histological assessment on inﬂammation
and healing was performed using standardized score
systems (11).
PERI-STRUT FIBRIN DEPOSITION EVALUATION. Digital
images of vascular cross sections were captured using
an Olympus VS120 slide scanner (10, Olympus
America, Center Valley, Pennsylvania). Each digital
image was masked in Adobe Photoshop (version 14,
San Jose, California) to obscure image background
and nonintimal tissue. Using Image-Pro Plus (version
7, Media Cybernetics, Rockville, Maryland), the
masked images were segmented in a 24-bit hue-
saturation-intensity model for ﬁbrin and ﬁbrous tis-
sue and the area of tissues in each hue segment was
measured in microns. The hue segmentation was then
used to create a mask displaying all pixels in either
segment as black, and the mask area was measured
for a baseline area value. The percentages of ﬁbrin
and ﬁbrous tissue were calculated with the formula:
(segment area/baseline area)  100.
STATISTICAL ANALYSIS. Statistical analysis was
conducted using the statistical software SigmaStat
(version 3.5, Systat Software, San Jose, California).FIGURE 2 Particulate Formation Following Paclitaxel Balloon Inﬂat
(A) Qualitative appearance of the amount of coating particulate produc
including particles $300 mm in size.Parametric data (angiographic and histomorpho-
metric) were analyzed by 1-way analysis of variance
(ANOVA) if the data were normally distributed and
the variances homogeneous. Otherwise data were
analyzed by Kruskal-Wallis ANOVA. When the
ANOVA was signiﬁcant, post-hoc testing was con-
ducted comparing the 3 individual DCB technologies
versus the control technology using the Holm-Sidak
test. Nonparametric data (qualitative histopathology
scores) were analyzed with Kruskal-Wallis 1-way
ANOVA. If the ANOVA was signiﬁcant, post-hoc
testing was conducted comparing the 3 individual
DCB technologies versus control technology using the
Dunn test. Differences were only considered signiﬁ-
cant when the calculated p value was <0.05.
RESULTS
PARTICULATE FORMATION AND PACLITAXEL
TISSUE LEVELS. In the bench top study, the Ranger
PCB had fewer observable particles than either Luto-
nix or In.Pact Paciﬁc (Figure 2A). In the quantitative
analysis, the average number of large particles
(<300 mm) was approximately 6 to 8 lower than for
both Lutonix and In.Pact Paciﬁc (Figure 2B).ion
ed by each drug-coated balloon tested. (B) Quantitative analysis
TABLE 1 Angiographic Data at All Time Points
Control Group Ranger Group In.Pact Group Lutonix Group p Value
Injury, Day 0
RVD, mm 4.42  0.82 4.25  0.59 4.57  0.44 4.28  0.38 0.76
MLD, mm 4.12  0.79 3.97  0.42 4.25  0.42 3.99  0.38 0.77
BAR 1.23  0.04 1.26  0.16 1.15  0.08 1.26  0.17 0.41
SAR 1.14  0.19 1.13  0.16 1.15  0.17 1.14  0.19 0.99
Treatment, Day 14
MLD, mm 3.28  0.73 3.23  0.6 3.66  0.88 3.86  0.75 0.41
%DS 19  11 19  11 18  12 20  12 0.49
MLD post, mm 4.06  0.62 3.41  0.46 4.08  0.71 3.77  0.64 0.22
Termination, Day 42
RVD, mm 4.59  0.79 4.16  0.56 4.47  0.63 4.16  0.62 0.56
MLD, mm 0.99  0.52 2.9  0.55* 3.44  0.65* 2.87  0.41* <0.05
%DS 79  12 29  8* 23  10* 30  12* <0.05
Late loss, mm 3.07  0.37 0.51  0.42* 0.65  0.74* 0.91  0.3* <0.05
Values are mean  SD. *If p < 0.05 from uncoated group.
BAR ¼ balloon-to-artery ratio; %DS ¼ percentage of diameter stenosis; MLD ¼ minimal lumen diameter;
RVD ¼ reference vessel diameter; SAR ¼ stent-to-artery ratio.
FIGURE 3 Comparative Tissue Levels of a Standard Dose PCB
Versus a Lower-Dose Balloon
Comparative tissue levels up to 60 days of a standard dose
paclitaxel-coated balloon (PCB) (In.Pact) versus a lower-dose
balloon (Ranger) in the superﬁcial femoral artery territory of the
swine. Dashed line represents the comparative data with the
Lutonix PCB (11). DCB ¼ drug-coated balloon.
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1119Figure 3 shows the arterial paclitaxel tissue con-
centration proﬁles of each PCB over time. All PCB
technologies displayed comparable levels of acute
tissue transfer following balloon inﬂation. At 24 h,
paclitaxel tissue levels decreased to w20 ng/mg in
both Ranger and In.Pact groups versus w5 ng/mg in
the Lutonix group (11). At 7 days, both Ranger and
In.Pact displayed a decrease in tissue levels of
w50%. At the same time point, the tissue levels in
the Lutonix group had already dropped down tow1 to
2 ng/mg. In contrast, paclitaxel tissue levels were still
several fold higher than this level at 21 days in the
Ranger and In.Pact PCB groups and slowly decreased
to w1 to 2 ng/mg at 30 days in both groups.
IN-STENT RESTENOSIS EFFICACY STUDY. Angio-
graph ic ana lys i s . The QVA analysis is summarized in
Table 1. Angiographic variables at baseline and at
2 weeks before PCB treatment were comparable among
all tested groups. Minimum lumen diameter was
unchanged immediately after treatment with PCB or
control balloon. At day 42, terminal angiographic
analysis demonstrated reduction in percentage of
diameter stenosis among all PCB-treated vessels when
compared with the uncoated control. Angiographic
late lumen loss was lowest in the Ranger balloon
(0.51  0.42 mm) versus In.Pact (0.65  0.74 mm) and
Lutonix (0.91  0.3 mm). Representative angiographic
images from days 14 and 42 are shown in Figure 4.
HISTOLOGICAL ANALYSIS. A summary of histological
data is presented in Table 2. When compared with the
control balloon group, all PCB groups demonstrated
signiﬁcantly greater lumen areas and levels of
neointimal inhibition as determined by reduced
neointimal thickness and percentage of area stenosis.
The neointima maturity score was the lowest in
In.Pact compared with the other DCB and the uncoated
control balloon. The percentage and distribution of
peri-strut ﬁbrin deposits is shown in Figure 5. Com-
pared with other PCB groups, the In.Pact PCB group
displayed a higher number of struts covered by ﬁbrin.
DISCUSSION
PCB technologies are emerging as the therapy of choice
for peripheral vascular interventions. The pharmaco-
kinetic proﬁle of PCB relies on the properties of the
coating. In turn, coating properties are the result of the
type of excipient and manufacturing process used to
develop the coating. In general, crystalline coatings,
compared with amorphous coatings, result in pro-
longed tissue level retention; however, crystalline
coatings are limited by heterogeneous drug tissue
uptake and neointimal inhibition (10). The ﬁrst-generation PCB technology used a crystalline coating
formulation (3 mg/mm2) and showed signiﬁcant
decrease in angiographic restenosis among patients
undergoing percutaneous intervention of the superﬁ-
cial femoral artery (1). Despite its initial clinical suc-
cess, technology acceptance was hampered by the
FIGURE 4 Representative Angiography and Histology Images at Termination
Representative angiography (E, F, G, H) and histology (I, J, K, L) images were taken at termination (day 42). The control, uncoated balloon
group showed the highest neointimal proliferation (E, I) when compared with all drug-coated balloon groups.
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for downstream particle embolization (4). Newer-
generation PCB aimed to improve these technical
limitations by either modifying the degree of coating
crystallinity or by decreasing the total paclitaxel con-
centration loaded on the surface of the balloon (2,5). To
date, the impact of these technological changes on
tissue pharmacokinetics and clinical efﬁcacy are still
under investigation.In the early stages of PCB development, the safety
proﬁle of this ﬁrst-generation technology was ques-
tioned due to the high amount of coating particulate
produced following balloon inﬂation. At the pre-
sent time, although the potential impact of coating
particulate dislodgement on microvessel embolization
remains a theoretical concern, a clinical below-the–
knee trial (18) using a speciﬁc PCB technology demon-
strated increased amputation rates raising questions
FIGURE 5 Percentage and Distribution of Peri-Strut Fibrin Deposits in All Drug-Coated Balloon Groups Versus Controls
TABLE 2 Histomorphometry and Qualitative Histological Analysis at Termination
Control Group Ranger Group In.Pact Group Lutonix Group p Value
EEL area, mm2 22.19  3.84 22.5  3.7 22.45  4.39 23.02  3.75 0.94
IEL area, mm2 20  2.82 20.6  3 20.67  3.52 21.12  3.1 0.78
Stent area, mm2 19.91  2.78 20.38  2.76 20.08  2.89 20.97  2.99 0.77
Lumen area, mm2 3.59  2.43 9.97  2.46* 11.81  2.96* 10.42  3.64* <0.05
%AS 82  14 52  7* 43  9* 52  12* <0.05
NIA, mm2 16.41  4.09 10.63  1.52* 8.86  2.2* 10.69  1.71* <0.05
NIT, mm 1.54  0.36 0.79  0.11 0.64  0.15* 0.8  0.19 <0.05
Neointima inﬂammation 0.63  0.5 0.9  0.11 0.55  0.46 0.43  0.41 0.32
Neointima maturity 2.9  0.11 1.87  0.66* 1.48  0.74* 1.88  0.49* <0.05
Fibrin deposition 0.0  0.0 0.17  0.26 0.76  0.40* 0.32  0.32 <0.05
Values are mean  SD. *If p < 0.05 compared with control group.
%AS ¼ percentage of area stenosis; EEL ¼ external elastic lamina; IEL ¼ internal elastic lamina; NIA ¼ neointimal area; NIT ¼ neointimal thickness.
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PERSPECTIVES
WHAT IS KNOWN? The ideal PCB dose for periph-
eral vascular interventions has not been established
yet. In this study we compared the biological effect on
restenosis and healing of a standard dose PCB with 2
lower-dose PCB concepts.
WHAT IS NEW? The data showed that lower-dose
PCB technologies achieved lower long-term tissue
levels but comparable degree of neointimal inhibition
and fewer ﬁbrin deposits than did the clinically estab-
lished PCB dose.
WHAT IS NEXT? The study established the potential
boundaries of clinical safety and efﬁcacy of PCB
technologies.
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1122about embolization as a potential mechanism for these
outcomes. In our study, there was aw30% (Lutonix) to
90% (Ranger) reduction in the number of large particles
in the 2-mg/mm2 technology versus the 3-mg/mm2
technology (In.Pact). These differences are important
as large particles have the potential to occlude
microvessels downstream following balloon inﬂation.
However, although these ﬁndings are theoretically
appealing, their clinical relevance is unknown.
The tissue pharmacokinetic study also demon-
strated that other variables besides total paclitaxel
concentration determine long-term tissue retention
in PCB technologies. In this study, we demonstrated
that a lower-dose PCB, compared with the clinically
established PCB dose, has the potential to achieve
long-term tissue levels of paclitaxel. However,
important differences were seen at the early time
points in all 3 technologies. Whereas paclitaxel tissue
levels are comparable among all 3 devices following
balloon inﬂation, there is a sharp drop in the Lutonix
tissue levels at 24 h compared with tissue levels for
the other 2 PCB tested. Also, although the pharma-
cokinetic curve of the In.Pact and Ranger technolo-
gies were comparable over time, the In.Pact balloon
achieved higher tissue levels after 7 days of initial
delivery. This is an important ﬁnding as it shows that
a comparable surrogate of clinical efﬁcacy (tissue
levels) could be demonstrated at lower paclitaxel
balloon concentrations; therefore, there is potential
to demonstrate comparable positive clinical out-
comes as clinical data become available.
Our study also demonstrated that histology-based
neointimal inhibition was comparable among all
PCB technologies regardless of excipient type or
paclitaxel density. The higher density PCB (3 mg/
mm2), compared with the lower density PCB (2 mg/
mm2), showed slightly higher levels of neointimal
inhibition but also reduced neointimal maturity and
higher ﬁbrin deposition, suggesting that reduced
paclitaxel density leads to slightly lower neointimal
inhibition but better healing proﬁles. Although only
the Ranger and Lutonix PCB can be directly compared
(as they use the same paclitaxel densities and thus
differ by only 1 variable), each coating excipient
demonstrated similar levels of neointimal inhibition.
This data is important as it shows that the differences
seen in tissue levels in the early time points may not
signiﬁcantly impact the late development of neo-
intimal inhibition in the experimental setting.
The technological developments in the PCB ﬁeld
continue to evolve. The ideal PCB has been deﬁned as
achieving a uniform coating that minimizes the quan-
tity of particles released and provides maximal drug
retention with minimal vascular toxicity. Althoughimportant differences exist among all the coating
technologies, our study suggests that the pharmaco-
logical behavior and tissue effects of the lower-dose
PCB concepts are comparable to the clinically proven
standard dose balloon. This is an important ﬁnding as
it continues to expand our knowledge in regard to the
therapeutic thresholds of local drug delivery devices in
the peripheral vascular territory.
STUDY LIMITATIONS. First, the experimental nature
of the study may limit the translation of our ﬁndings to
the human condition. Second, we used the 28-day
follow-up time point for the evaluation of efﬁcacy. It
is possible that some of the differences seen in tissue
levels among all devices could reﬂect important dif-
ferences at later timepoints not evaluated in this study.
Finally, the lack of a signiﬁcant atherosclerotic burden
found in this model takes away important biological
components known to be critical for the success of local
drug delivery devices in humans (e.g., calcium).
CONCLUSIONS
Lower dose PCB technologies achieved lower long-
term tissue levels but comparable degrees of neo-
intimal inhibition and fewer peri-strut ﬁbrin deposits
than did the clinically established PCB dose. The
impact of these ﬁndings in restenosis reduction and
clinical outcomes needs to be further investigated.
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